RNA Formulation Videos

1. An Early Formulation Screening Service 5/23/2024

   Gain insights into overcoming the challenges in lipid nanoparticle (LNP) formulation, explore critical aspects of the process and analytical development of LNPs, and much more.

2. Modular Liquid Nanoparticle (LNP) Systems 12/6/2024

   Optimize your lipid nanoparticle (LNP) production with KNAUER's modular systems. Maximize flexibility, scalability, and control to meet the needs of your project.

3. Advancements In LNP CMC: What Are The Current "Known Knowns"? 12/4/2024

   In this Advancing RNA Live clip, Sanofi’s Sumit Luthra highlights the learnings we’ve made to-date about how our processes — both in terms of unit operations and process conditions — inform our LNP composition/heterogeneity.

4. CRISPR Meets LNPs: A New Era In Cell And Gene Therapies 7/8/2025

   Explore how lipid nanoparticles are revolutionizing non-viral gene editing with scalable, efficient delivery for both ex vivo and in vivo applications, which features new CRISPR-LNP data in T cells.

5. Addressing Industry Challenges In mRNA Product Commercialization

   While the speed of production and flexibility of mRNA are appealing, several industry challenges must still be addressed to realize the full potential and further expand its use.

6. R&D & CMC Priorities For LNPs Beyond Cell-Specific Delivery 12/4/2024

   It goes without saying that achieving cell-specific delivery is the most often discussed challenge facing the RNA-LNP field near- and long-term. However, as these three LNP experts share in this Advancing RNA Live clip, they have a whole list of additional R&D and CMC priorities we must address/accomplish to improve RNA-LNPs’ efficacy in personalized and gene therapy approaches.

7. Goldilocks & The 3…CQAs? Finding "Just Right" With LNP Optimization 12/4/2024

   Three LNP experts from Sanofi, Hopewell Therapeutics, and BioNTech collectively discuss how far we’ve come in understanding the structure of our LNPs while also shedding light on the variables that have the greatest potential of causing shifts in our products’ structure/function.

8. The Scientific Underpinnings Of mRNA/LNPs 11/28/2022

   In this video, Russell Johnson, VP Formulation Research for RVAC Medicines, and Aalok Shah, Director of Formulation & Drug Delivery, Strand Therapeutics, share their thoughts on the scientific-research and CMC-related reasons that have made the lipid nanoparticle the “darling” of the delivery world for mRNA/RNA products today.

9. Next-Generation RNA Modality Supply Considerations

   Together, Life Edit Therapeutics’ April Sena and Sanofi’s Troiano share their perspectives on raw material quality & IP-related considerations for managing the supply chain for next-generation RNA modalities.

10. Molecular And Colloidal Ionization Properties Of Lipid Nanoparticle mRNA Vaccines 4/13/2022

    Dr. Michael Buschmann, George Mason University, presents an overview of molecular and colloidal ionization properties of lipid nanoparticle mRNA vaccines.